Activation of ADAM17 (A Disintegrin and Metalloprotease 17) on Glutamatergic Neurons Selectively Promotes Sympathoexcitation.
ADAM17 Protein
/ metabolism
Angiotensin II
/ pharmacology
Animals
Autonomic Nervous System
/ metabolism
Blood Pressure
/ physiology
Disease Models, Animal
Hypertension
/ chemically induced
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Neurons
/ metabolism
Paraventricular Hypothalamic Nucleus
/ metabolism
Sodium Chloride, Dietary
/ toxicity
central nervous system
immune system
mice
neurons
renin-angiotensin system
Journal
Hypertension (Dallas, Tex. : 1979)
ISSN: 1524-4563
Titre abrégé: Hypertension
Pays: United States
ID NLM: 7906255
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
23
4
2019
medline:
19
11
2019
entrez:
23
4
2019
Statut:
ppublish
Résumé
Chronic activation of the brain renin-angiotensin system contributes to the development of hypertension by altering autonomic balance. Beyond the essential role of Ang II (angiotensin II) type 1 receptors, ADAM17 (A disintegrin and metalloprotease 17) is also found to promote brain renin-angiotensin system overactivation. ADAM17 is robustly expressed in various cell types within the central nervous system. The aim of this study was to determine whether ADAM17 modulates presympathetic neuronal activity to promote autonomic dysregulation in salt-sensitive hypertension. To test our hypothesis, ADAM17 was selectively knocked down in glutamatergic neurons using Cre-loxP technology. In mice lacking ADAM17 in glutamatergic neurons, the blood pressure increase induced by deoxycorticosterone acetate-salt treatment was blunted. Deoxycorticosterone acetate-salt significantly elevated cardiac and vascular sympathetic drive in control mice, while such effects were reduced in mice with ADAM17 knockdown. This blunted sympathoexcitation was extended to the spleen, with a lesser activation of the peripheral immune system, translating into a sequestration of circulating T cells within this organ, compared with controls. Within the paraventricular nucleus, Ang II-induced activation of kidney-related presympathetic glutamatergic neurons was reduced in ADAM17 knockdown mice, with the majority of cells no longer responding to Ang II stimulation, confirming the supportive role of ADAM17 in increasing presympathetic neuronal activity. Overall, our data highlight the pivotal role of neuronal ADAM17 in regulating sympathetic activity and demonstrate that activation of ADAM17 in glutamatergic neurons leads to a selective increase of sympathetic output, but not vagal tone, to specific organs, ultimately contributing to dysautonomia and salt-sensitive hypertension.
Identifiants
pubmed: 31006330
doi: 10.1161/HYPERTENSIONAHA.119.12832
pmc: PMC6506373
mid: NIHMS1524626
doi:
Substances chimiques
Sodium Chloride, Dietary
0
Angiotensin II
11128-99-7
ADAM17 Protein
EC 3.4.24.86
Adam17 protein, mouse
EC 3.4.24.86
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1266-1274Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL135635
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104940
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL084207
Pays : United States
Organisme : BLRD VA
ID : I01 BX004249
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM106392
Pays : United States
Organisme : BLRD VA
ID : I01 BX004294
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL093178
Pays : United States
Références
J Pharmacol Exp Ther. 2005 Jun;313(3):1035-45
pubmed: 15681656
Basic Res Cardiol. 2011 Nov;106(6):1087-97
pubmed: 21892747
Am J Physiol Heart Circ Physiol. 2014 Nov 15;307(10):H1448-55
pubmed: 25217656
Hypertension. 2007 Apr;49(4):926-31
pubmed: 17325232
Cardiovasc Toxicol. 2013 Mar;13(1):48-54
pubmed: 22971929
Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1557-66
pubmed: 19717736
J Neurochem. 2007 Mar;100(5):1407-20
pubmed: 17241124
Brain Res. 2012 Apr 4;1447:28-37
pubmed: 22356885
Front Physiol. 2016 Oct 18;7:469
pubmed: 27803674
J Cereb Blood Flow Metab. 2002 May;22(5):576-85
pubmed: 11973430
Circ Res. 2013 Oct 12;113(9):1087-1096
pubmed: 24014829
PLoS One. 2017 Mar 28;12(3):e0174780
pubmed: 28350885
J Physiol. 2018 Dec;596(24):6235-6248
pubmed: 30151830
Eur J Neurosci. 2005 Aug;22(3):658-64
pubmed: 16101747
J Immunol. 2007 Apr 1;178(7):4214-21
pubmed: 17371977
J Physiol. 2015 Jul 15;593(14):3065-75
pubmed: 26173827
Hypertension. 2017 Jan;69(1):154-162
pubmed: 27802416
Cardiovasc Res. 2018 Mar 01;114(3):456-467
pubmed: 29324984
Hypertension. 2009 Feb;53(2):210-6
pubmed: 19124678
Clin Sci (Lond). 2013 Jul 1;125(2):57-65
pubmed: 23530669
Hypertension. 2016 Dec;68(6):1483-1493
pubmed: 27698069
Toxicol Appl Pharmacol. 2014 Nov 15;281(1):101-8
pubmed: 25223692
Endocrinology. 2008 Dec;149(12):6053-64
pubmed: 18687778
Curr Hypertens Rep. 2010 Jun;12(3):170-5
pubmed: 20424953
J Neurophysiol. 2007 May;97(5):3279-87
pubmed: 17287434
J Am Coll Cardiol. 2001 Nov 15;38(6):1711-7
pubmed: 11704385
Nat Commun. 2016 Sep 27;7:13035
pubmed: 27676657
Exp Physiol. 2005 Sep;90(5):663-70
pubmed: 15944202
J Neurosci. 2013 Oct 2;33(40):15879-93
pubmed: 24089494
Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1675-82
pubmed: 17185407
Neuropsychopharmacology. 2002 Feb;26(2):155-63
pubmed: 11790511
Circ Res. 2017 Jun 23;121(1):43-55
pubmed: 28512108
Curr Opin Pharmacol. 2011 Apr;11(2):124-30
pubmed: 21159555
J Nutr. 2000 Apr;130(4S Suppl):1007S-15S
pubmed: 10736372
Science. 2002 Mar 22;295(5563):2282-5
pubmed: 11910117
Neuropharmacology. 2016 Jun;105:114-123
pubmed: 26767952
J Neurosci. 2014 Sep 3;34(36):11884-96
pubmed: 25186737
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1955-60
pubmed: 12578975